Anavex Life Sciences Corp (AVXL)

[apostrophe]

re: "The control patients in the PRAN trial had amyloid results that were never seen in any previous trial. It put the whole trial in question and was never accounted for. "

Do you mean this?

http://www.biospace.com/News/prana-biotechnology-tanks-as-lead-drug-fails/328526

There have already been many posts on why excess amyloid production is a result not the cause. There is still a lot of hype (though few seem to see it that way) and tunnel vision on blowing away/dissolving the plaque and tangles, neutralizing the precursor to kill amyloid production, etc. Of course it will ultimately fail because the cell is still sick. 2-73 repairs what is making the cell go hay-wire internally (geez, I almost said the "C" word... :) ) , it actually makes them healthy again unlike all previous attempts that fail to look under the hood.

The reason there have been so many failed trials in the past is that most have been repeat variations on the same theme when they have not been off the mark completely (e.g. attacking with cloned antibodies). The two main categories have been: 1. Boost acetylcholine , 2. Eliminate amyloid

Also there was never sustained and marked improvement hence the larger groups to try to squeeze out statistical significance. There also seems to be some industry bias, for example that the Aricept deaths showing up statistically conversely could be dismissed as not significant.